Omeros Debuts With $68 Million IPO Despite Legal Hassles from Former CFO
Investors push the stock down on its first day, but the Seattle biotech now has cash to help get its late-stage pain compound to market.
Investors push the stock down on its first day, but the Seattle biotech now has cash to help get its late-stage pain compound to market.